Company announcement no. 7-2019                                                                                                            

Birkerød, 29 April 2019

ViroGates A/S (Nasdaq First North Denmark: VIRO) has revised its financial calendar for 2019:

20 March             Deadline for submission of business to be transacted at the 2019 Annual General Meeting
27 March             Annual Report 2018
25 April                 Annual General Meeting
29 April                 Interim Report Q1 2019
21 August            Interim Report Q2 2019 (Changed from 29 July 2019)
28 October          Interim Report Q3 2019

The interim and annual financial reports will be available on Virogates’ website www.virogates.com immediately after their release.

For further information please contact:
CEO Jakob Knudsen:  Tel. (+45) 2113 1336, Email: jk@virogates.com

Certified Advisor
Västra Hamnen Corporate Finance, Per Lönn: Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates
ViroGates is an international medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 350,000 blood samples.

Attachment